Aclidinium bromide vs Tiotropium bromide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Aclidinium bromide · Tudorza Pressair
Marketed by Azurity Pharmaceuticals and partners
NCT00363896 · Phase 3 · completed
The trial randomized 843 participants to double-blind aclidinium or placebo, with trough FEV1 at 12 and 28 weeks, an accepted lung-function endpoint for COPD, as its primary outcome. The registry posts no significance test, but the publication of ACCLAIM/COPD I reports trough FEV1 improvements over placebo of 61 mL and 67 mL at 12 and 28 weeks (both p<0.001).
Reported efficacy
Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L. (met)
Result source: NCT03022097
Tiotropium bromide
Marketed by Boehringer Ingelheim
NCT02172287 · Phase 3 · completed
This 6-month trial randomly assigned 623 patients with COPD to tiotropium, salmeterol or placebo, with double-blind, double-dummy treatment. The two primary measures were trough FEV1 and the Transition Dyspnea Index (TDI). Tiotropium raised trough FEV1 by 0.14 L more than placebo, more than salmeterol did (0.09 L; p<0.01 for tiotropium against salmeterol), and improved the TDI focal score by 1.02 units against placebo (p=0.01). Both primary measures favoured tiotropium, so the result is met. The figures come from the peer-reviewed paper in Chest (2002).
Reported efficacy
Change from baseline in trough Forced expiratory volume in one second (FEV1) response (baseline, up to day 169); Change from baseline in Mahler Transitional Dyspnoea Index (TDI) (baseline, up to day 169): Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant. (met)
Result source: NCT02172287
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aclidinium bromide | Tiotropium bromide |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | 0.4 vs 0.6−0.1 vs placeboNCT01966107 | 0.9 vs 1.3−0.4 vs placeboNCT016639871 other result
|
| Trough FEV1, change | 0.1 vs -0.1+0.2 vs placeboNCT0302209725 other results
| 0.1 vs 0.1vs ABNCT0279667742 other results
|
| SGRQ total, change | -3.6 vs -1.9−1.8 vs placeboNCT015727927 other results
| -4.1 vs -2.0−2.1 vs placeboNCT00496470 |
| TDI focal score | 2.9 vs 2.1+0.8 vs placeboNCT030220975 other results
| —Not posted · NCT02172287 |
Moderate or severe exacerbations, annualised rate
- Aclidinium bromide
- 0.4 vs 0.6−0.1 vs placeboNCT01966107
- Tiotropium bromide
- 0.9 vs 1.3−0.4 vs placeboNCT01663987
1 other result
- 0.9 vs 1.3 NCT01662986
Trough FEV1, change
- Aclidinium bromide
- 0.1 vs -0.1+0.2 vs placeboNCT03022097
25 other results
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT01001494
- 0.1 vs -0.0 NCT01437397
- 0.1 vs -0.0 NCT01437397
- 0.1 vs -0.1 NCT01462942
- 0.1 vs -0.1 NCT01462942
- 1.2 vs 1.2 NCT00358436
- 1.2 vs 1.2 NCT00358436
- 0.1 vs -0.0 NCT00891462
- 0.1 vs -0.0 NCT01045161
- 0.1 vs -0.0 NCT01001494
- 0.0 vs -0.1 NCT01001494
- 0.1 vs -0.0 NCT00891462
- 0.0 vs -0.0 NCT01045161
- 0.0 vs -0.0 NCT01001494
- 0.1 vs 0.1 NCT02796677
- 0.0 vs -0.1 NCT01572792
- 0.0 vs -0.1 NCT01572792
- 0.1 vs -0.0 NCT00500318
- 0.1 vs -0.0 NCT02153489
- 0.1 vs -0.0 NCT01120093
- 0.1 vs -0.0 NCT01120093
- 0.1 vs -0.0 NCT01120093
- Tiotropium bromide
- 0.1 vs 0.1vs ABNCT02796677
42 other results
- 0.2 vs -0.1 NCT01663987
- 0.2 vs 0.1 NCT01662986
- 0.1 vs 0.1 NCT03118765
- 0.1 vs 0.1 NCT03118765
- 0.1 vs 0.1 NCT03118765
- 0.2 vs 0.1 NCT00696020
- 0.1 vs 0.1 NCT00696020
- 0.1 vs 0.1 NCT00696020
- 0.1 vs -0.0 NCT00359788
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.0 NCT00523991
- 0.1 vs -0.0 NCT00523991
- 0.2 vs 0.0 NCT01663987
- 0.2 vs 0.0 NCT01662986
- 0.1 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.0 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.1 vs -0.0 NCT00359788
SGRQ total, change
- Aclidinium bromide
- -3.6 vs -1.9−1.8 vs placeboNCT01572792
7 other results
- -5.5 vs -1.9 NCT01572792
- -8.7 vs -4.7 NCT03022097
- -7.6 vs -4.7 NCT03022097
- -6.6 vs -2.2 NCT01437397
- -5.9 vs -2.2 NCT01437397
- -7.2 vs -6.5 NCT01462942
- -8.3 vs -6.5 NCT01462942
- Tiotropium bromide
- -4.1 vs -2.0−2.1 vs placeboNCT00496470
TDI focal score
- Aclidinium bromide
- 2.9 vs 2.1+0.8 vs placeboNCT03022097
5 other results
- 2.6 vs 2.1 NCT03022097
- 2.0 vs 0.6 NCT01437397
- 2.0 vs 0.6 NCT01437397
- 2.5 vs 1.2 NCT01462942
- 2.4 vs 1.2 NCT01462942
- Tiotropium bromide
- —Not posted · NCT02172287
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety
Coverage. Aclidinium bromide: 13 of 13 rows · Tiotropium bromide: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aclidinium bromide Rows use multiple source trials | Tiotropium bromide Rows use multiple source trials |
|---|---|---|
| FEV1 AUC0-12h absolute change · L | 0.236 vs 0.015 placebo L @ 2.142857142857143wk400 μg Bida,b,c NCT00868231 · Phase 2 · registry result, not featured evidence | 0.23 vs 0.08 placebo L @ 3wk10 μgd,a,b,c NCT03118765 · Phase 2 · registry result, not featured evidence show 2 more doses0.15 vs 0.08 placebo L @ 3wk40 μg NCT03118765 · Phase 2 · registry result, not featured evidence 0.17 vs 0.08 placebo L @ 3wk20 μg NCT03118765 · Phase 2 · registry result, not featured evidence |
| FEV1 AUC0-3h absolute change · L | 0.237 vs 0.162 AB L @ 24wk400/12 μge,a,b NCT02796677 · Phase 3 · registry result, not featured evidence | 0.16 vs -0.06 placebo L @ 24wke,a,b NCT00523991 · Phase 4 · registry result, not featured evidence 1 other source trial0.237 vs 0.162 AB L @ 24wk400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence |
| FEV1 Change 1h absolute change · L | 0.156 vs -0.05 placebo L @ 24wk400 μgd,a,b NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 1 more dose0.248 vs -0.05 placebo L @ 24wk400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 | 0.253 vs 0.169 AB L @ 24wk400/12 μga,b NCT02796677 · Phase 3 · registry result, not featured evidence |
| FEV1 Peak absolute change · L | 0.225 vs 0.008 placebo L @ 24wk400 μgd,e,a,b NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 1 more dose0.324 vs 0.008 placebo L @ 24wk400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 | 0.26 vs 0.02 placebo L @ 24wke,a,b NCT00523991 · Phase 4 · registry result, not featured evidence 3 other source trials0.216 vs 0.051 placebo L @ 24wk100 mcg NCT00528996 · Phase 2 · registry result, not featured evidence 0.216 vs 0.051 placebo L @ 24wk200 mcg NCT00528996 · Phase 2 · registry result, not featured evidence 0.207 vs 0.051 placebo L @ 24wk50 mcg NCT00528996 · Phase 2 · registry result, not featured evidence |
| FEV1 Peak absolute change · L No placebo or comparator arm | 0.172 L @ 52wk400 μgd,f,a,g NCT01045161 · Phase 3 show 1 more dose0.176 L @ 52wk200 μg to 400 μg NCT01045161 · Phase 3 | 0.264 L @ 4wk5 mcgd,f,a,g NCT01040403 · Phase 2 · registry result, not featured evidence show 7 more doses0.267 L @ 4wk10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence 0.412 L @ 4wktiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.379 L @ 4wktiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.399 L @ 4wktiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.355 L @ 4wktiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.374 L @ 4wktiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.353 L @ 4wktiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination |
| FEV1 Trough absolute value · L | 1.428 vs 1.366 placebo L @ 12wk200 μg Once-dailye,a,b NCT00363896 · Phase 3 · monotherapy | 1.225 vs 1.119 Combivent (Ipratropium/Albuterol) L @ 12wke,a,b NCT00359788 · Phase 4 · registry result, not featured evidence |
| FEV1 Trough absolute change · L No placebo or comparator arm | 0.048 L @ 52wk400 μgd,a,b,h NCT01045161 · Phase 3 show 1 more dose0.029 L @ 52wk200 μg to 400 μg NCT01045161 · Phase 3 | 1.285 L @ 120wk5 mcgd,a,b,h NCT01126437 · Phase 3 · registry result, not featured evidence show 2 more doses1.295 L @ 120wk18 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 1.258 L @ 120wk2.5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence |
| SGRQ responder rate · % of participants Number of responders -Yes | 48.1% (n=270) vs 49.1% (n=383) AB @ 24wk*400/12 μga,b Number of responders -Yes NCT02796677 · Phase 3 · registry result, not featured evidence · converted to % from 130 Participants as posted | 48.1% (n=270) vs 49.1% (n=383) AB @ 24wk*400/12 μga,b Number of responders -Yes NCT02796677 · Phase 3 · registry result, not featured evidence · converted to % from 130 Participants as posted |
| Time to First Exacerbation time to event · months | NA vs NA placebo months @ 52wk200 μg Once-dailye,a,i NCT00363896 · Phase 3 · monotherapy | 0.1 vs 0.33 TIO months*50/250 µg BIDd,e,a,i NCT01762800 · Phase 4 · registry result, not featured evidence · converted to months from 3 days as posted show 5 more doses0 vs 0 TIO months*50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · converted to months from 0 days as posted 0.16 vs 0.33 TIO months*50/250 µg BID + 18 µg QD NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 5 days as posted 0 vs 0 TIO months*50/250 µg BID + 18 µg QD NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 0 days as posted 0.07 vs 0.33 TIO months*18 µg QD + 50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 2 days as posted 0.03 vs 0 TIO months*18 µg QD + 50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 1 days as posted |
| Dropout rate | 14.2%200 μg Once-dailyj NCT00363896 · Phase 3 · monotherapy show 34 more results25.7%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 7.1%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.9%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 —400 μg Bid NCT01120093 · Phase 2 —200 μg Bid NCT01120093 · Phase 2 —100 μg Bid NCT01120093 · Phase 2 12.6%400µg NCT00891462 · Phase 3 17.8%200µg NCT00891462 · Phase 3 —400 μg NCT01045161 · Phase 3 —400 μg NCT01045161 · Phase 3 —200 μg NCT01045161 · Phase 3 —200 μg to 400 μg NCT01045161 · Phase 3 6.3%400 μg Bid NCT01001494 · Phase 3 8.7%200 μg Bid NCT01001494 · Phase 3 44.3% NCT01966107 · Phase 4 4.4%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence —400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 19.5%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 18.3%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 19.5%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 18.3%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 8.8%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 10.5%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence —400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 2.9%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 44.7%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 42.6%200µg NCT01044459 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 5.8% NCT00500318 · Phase 3 · registry result, not featured evidence —400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence | 10.3%50/250 µg BIDk NCT01762800 · Phase 4 · registry result, not featured evidence show 37 more results—50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01762800 · Phase 4 · registry result, not featured evidence · combination —18 µg QD + 50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · combination 15%18μg NCT01663987 · Phase 4 · registry result, not featured evidence 33.3%18 μg NCT01662986 · Phase 4 · registry result, not featured evidence —50/250 µg BID NCT01751113 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01751113 · Phase 4 · registry result, not featured evidence · combination 11.3% NCT00523991 · Phase 4 · registry result, not featured evidence 7.9% NCT00496470 · Phase 4 · registry result, not featured evidence · combination 13.3% NCT00359788 · Phase 4 · registry result, not featured evidence — NCT03137992 · Phase 3 · registry result, not featured evidence —5 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence 0%18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 23.2%5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 23%18 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 23.4%2.5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence —150 μg NCT00999908 · Phase 3 · registry result, not featured evidence 13.3%10 μg NCT03118765 · Phase 2 · registry result, not featured evidence 16.1%40 μg NCT03118765 · Phase 2 · registry result, not featured evidence 6.3%20 μg NCT03118765 · Phase 2 · registry result, not featured evidence —5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —18 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 4.5%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 2.2%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 3.2%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 3.8%200 μg Once-dailyj NCT00363896 · Phase 3 · monotherapy show 34 more results4.8%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 1.5%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 1.1%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 —400 μg Bid NCT01120093 · Phase 2 —200 μg Bid NCT01120093 · Phase 2 —100 μg Bid NCT01120093 · Phase 2 3.7%400µg NCT00891462 · Phase 3 4.3%200µg NCT00891462 · Phase 3 —400 μg NCT01045161 · Phase 3 —400 μg NCT01045161 · Phase 3 —200 μg NCT01045161 · Phase 3 —200 μg to 400 μg NCT01045161 · Phase 3 1.5%400 μg Bid NCT01001494 · Phase 3 2.9%200 μg Bid NCT01001494 · Phase 3 — NCT01966107 · Phase 4 1.5%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence —400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 6.2%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.5%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.2%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 6.5%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 3.1%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 2.6%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence —400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 1.8%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 6.8%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 7.1%200µg NCT01044459 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 3.5% NCT00500318 · Phase 3 · registry result, not featured evidence —400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence | 6.4%50/250 µg BIDk NCT01762800 · Phase 4 · registry result, not featured evidence show 37 more results—50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01762800 · Phase 4 · registry result, not featured evidence · combination —18 µg QD + 50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · combination 5%18μg NCT01663987 · Phase 4 · registry result, not featured evidence 10.3%18 μg NCT01662986 · Phase 4 · registry result, not featured evidence —50/250 µg BID NCT01751113 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01751113 · Phase 4 · registry result, not featured evidence · combination 2.1% NCT00523991 · Phase 4 · registry result, not featured evidence 2.4% NCT00496470 · Phase 4 · registry result, not featured evidence · combination 6.4% NCT00359788 · Phase 4 · registry result, not featured evidence — NCT03137992 · Phase 3 · registry result, not featured evidence —5 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 10.6%5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 11.1%18 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 10.5%2.5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence —150 μg NCT00999908 · Phase 3 · registry result, not featured evidence 3.3%10 μg NCT03118765 · Phase 2 · registry result, not featured evidence 3.2%40 μg NCT03118765 · Phase 2 · registry result, not featured evidence 3.1%20 μg NCT03118765 · Phase 2 · registry result, not featured evidence —5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —18 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 1.1%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 1.1%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 2.2%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 8%200 μg Once-dailyj NCT00363896 · Phase 3 · monotherapy show 34 more results10.3%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 7.9%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.2%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 1.4%400 μg Bid NCT01120093 · Phase 2 1.4%200 μg Bid NCT01120093 · Phase 2 0%100 μg Bid NCT01120093 · Phase 2 3.2%400µg NCT00891462 · Phase 3 4.3%200µg NCT00891462 · Phase 3 4.5%400 μg NCT01045161 · Phase 3 9.5%400 μg NCT01045161 · Phase 3 6%200 μg NCT01045161 · Phase 3 13%200 μg to 400 μg NCT01045161 · Phase 3 5.6%400 μg Bid NCT01001494 · Phase 3 4.3%200 μg Bid NCT01001494 · Phase 3 22.8% NCT01966107 · Phase 4 1.5%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence 0%400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence 7.3%400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 7.7%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.9%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 5.7%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 5.4%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 6%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 4.7%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence 0%400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 1.8%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 10%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 9.3%200µg NCT01044459 · Phase 3 · registry result, not featured evidence 12.3%400 μg NCT00970268 · Phase 3 · registry result, not featured evidence 15.2%400 μg NCT00970268 · Phase 3 · registry result, not featured evidence 14%200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 15.9%200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 2.3% NCT00500318 · Phase 3 · registry result, not featured evidence 0%400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence | —50/250 µg BIDk NCT01762800 · Phase 4 · registry result, not featured evidence show 37 more results5.9%50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence 8.8%50/250 µg BID + 18 µg QD NCT01762800 · Phase 4 · registry result, not featured evidence · combination 10.7%18 µg QD + 50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · combination 37.5%18μg NCT01663987 · Phase 4 · registry result, not featured evidence 25.6%18 μg NCT01662986 · Phase 4 · registry result, not featured evidence 0%50/250 µg BID NCT01751113 · Phase 4 · registry result, not featured evidence 3.8%50/250 µg BID + 18 µg QD NCT01751113 · Phase 4 · registry result, not featured evidence · combination 4.2% NCT00523991 · Phase 4 · registry result, not featured evidence 3% NCT00496470 · Phase 4 · registry result, not featured evidence · combination 6.4% NCT00359788 · Phase 4 · registry result, not featured evidence 0% NCT03137992 · Phase 3 · registry result, not featured evidence —5 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence 7.3%400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 32.9%5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 33.9%18 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 33.8%2.5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 0%150 μg NCT00999908 · Phase 3 · registry result, not featured evidence 0%10 μg NCT03118765 · Phase 2 · registry result, not featured evidence 0%40 μg NCT03118765 · Phase 2 · registry result, not featured evidence 0%20 μg NCT03118765 · Phase 2 · registry result, not featured evidence 2%5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 1.4%18 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 0%2.5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 1.4%1.25 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 3.7%5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence 1.8%10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence 0%tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 4.5%tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 2.7%tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 3.4%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 1.1%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 200 μg Once-dailyj nasopharyngitis 16.3% (placebo 14.4%) headache 11.3% (placebo 12.5%) back pain 4.8% (placebo 4.6%) NCT00363896 · Phase 3 · monotherapy show 34 more results200 μg once-daily headache 14.2% (placebo 12.7%) nasopharyngitis 12.7% (placebo 11.3%) upper respiratory tract infection 10.8% (placebo 9.8%) NCT00358436 · Phase 3 · monotherapy 400 μg upper respiratory tract infection 9.4% (placebo 8.9%) chronic obstructive pulmonary disease 7.9% (placebo 13%) NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg upper respiratory tract infection 11.8% (placebo 8.9%) chronic obstructive pulmonary disease 9.5% (placebo 13%) NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400 μg copd exacerbation 13% (placebo 11.5%) upper respiratory tract infection 1.7% (placebo 0.5%) nasopharyngitis 1.1% (placebo 0%) NCT01045161 · Phase 3 400 μg copd exacerbation 27.9% (placebo 11.5%) upper respiratory tract infection 5.4% (placebo 0.5%) nasopharyngitis 4.1% (placebo 0%) NCT01045161 · Phase 3 200 μg copd exacerbation 8.7% (placebo 11.5%) upper respiratory tract infection 1.6% (placebo 0.5%) nasopharyngitis 1.1% (placebo 0%) NCT01045161 · Phase 3 200 μg to 400 μg copd exacerbation 22.7% (placebo 11.5%) nasopharyngitis 5.8% (placebo 0%) upper respiratory tract infection 5.8% (placebo 0.5%) NCT01045161 · Phase 3 400 μg Bid chronic obstructivce pulmonary disease 14.1% (placebo 20.5%) headache 12.3% (placebo 8.1%) nasopharyngitis 11.2% (placebo 8.4%) NCT01001494 · Phase 3 200 μg Bid chronic obstructivce pulmonary disease 15.9% (placebo 20.5%) nasopharyngitis 11.6% (placebo 8.4%) headache 10.8% (placebo 8.1%) NCT01001494 · Phase 3 urinary tract infection 5% (placebo 4.7%) upper respiratory tract infection 4.8% (placebo 5.6%) viral upper respiratory tract infection 4.4% (placebo 3.7%) NCT01966107 · Phase 4 400 μg headache 5.2% (placebo 9.7%) nasopharyngitis 3% (placebo 6.7%) NCT02375724 · Phase 4 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary 15.6% nasopharyngitis 11.5% headache 5.1% NCT02796677 · Phase 3 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary disease 20.3% (placebo 15.8%) urinary tract infection 8.2% (placebo 5.5%) nasopharyngitis 7.7% (placebo 4.8%) NCT01572792 · Phase 3 · registry result, not featured evidence 400/6 μg chronic obstructive pulmonary disease 22.1% (placebo 15.8%) nasopharyngitis 6.9% (placebo 4.8%) urinary tract infection 6.4% (placebo 5.5%) NCT01572792 · Phase 3 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary disease 15.2% (placebo 17.5%) cough 5.1% (placebo 3.6%) nasopharyngitis 4.8% (placebo 3.6%) NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 400/6 μg chronic obstructive pulmonary disease 14.7% (placebo 17.5%) nasopharyngitis 5.1% (placebo 3.6%) cough 3.9% (placebo 3.6%) NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg chronic obstructive pulmonary disease 8.6% (placebo 11.9%) nasopharyngitis 7.8% (placebo 7.2%) headache 7.5% (placebo 8.2%) NCT01462942 · Phase 3 · registry result, not featured evidence 400/6 μg chronic obstructive pulmonary disease 9.4% (placebo 11.9%) nasopharyngitis 7.9% (placebo 7.2%) headache 7.1% (placebo 8.2%) NCT01462942 · Phase 3 · registry result, not featured evidence 400 μg BID nasopharyngitis 6.3% (placebo 3.7%) NCT01471171 · Phase 3 · registry result, not featured evidence 400 µg BID nasopharyngitis 6.4% (placebo 2.4%) headache 3.5% (placebo 4.7%) NCT01462929 · Phase 3 · registry result, not featured evidence 400µg chronic obstructive pulmonary disease 19.9% NCT01044459 · Phase 3 · registry result, not featured evidence 200µg chronic obstructive pulmonary disease 19.3% NCT01044459 · Phase 3 · registry result, not featured evidence 400 μg chronic obstructive pulmonary disorder 22.6% nasopharyngitis 9.4% urinary tract infection 7.5% NCT00970268 · Phase 3 · registry result, not featured evidence 400 μg chronic obstructive pulmonary disorder 30.4% contusion 10.9% cough 8.7% NCT00970268 · Phase 3 · registry result, not featured evidence 200 μg chronic obstructive pulmonary disorder 24.7% nasopharyngitis 8.6% back pain 7.5% NCT00970268 · Phase 3 · registry result, not featured evidence 200 μg chronic obstructive pulmonary disorder 36.4% sinusitis 11.4% upper respiratory tract infection 11.4% NCT00970268 · Phase 3 · registry result, not featured evidence cough 5.8% (placebo 3.2%) headache 5.8% (placebo 7.4%) upper respiratory tract infection 5.8% (placebo 2.1%) NCT00500318 · Phase 3 · registry result, not featured evidence 400 μg Bid diarrhoea 6.9% (placebo 0%) chronic obstructive pulmonary disease 0% (placebo 10%) NCT00868231 · Phase 2 · registry result, not featured evidence | 50/250 µg BIDk nasopharyngitis 18.4% dysphonia 13.2% bronchitis 5.1% NCT01762800 · Phase 4 · registry result, not featured evidence show 27 more results50/250 µg BID + 18 µg QD nasopharyngitis 20.6% bronchitis 10.3% dysphonia 8.8% NCT01762800 · Phase 4 · registry result, not featured evidence · combination 18 µg QD + 50/250 µg BID nasopharyngitis 26.7% dysphonia 8% bronchitis 6.7% NCT01762800 · Phase 4 · registry result, not featured evidence · combination 18μg chronic obstructive pulmonary disease 37.5% (placebo 43.6%) bronchitis 7.5% (placebo 5.1%) insomnia 5% (placebo 5.1%) NCT01663987 · Phase 4 · registry result, not featured evidence 18 μg chronic obstructive pulmonary disease 25.6% (placebo 15.4%) contusion 7.7% (placebo 0%) oedema peripheral 7.7% (placebo 0%) NCT01662986 · Phase 4 · registry result, not featured evidence 50/250 µg BID dysphonia 5.9% constipation 2% dry mouth 2% NCT01751113 · Phase 4 · registry result, not featured evidence 50/250 µg BID + 18 µg QD dysphonia 9.6% nasopharyngitis 5.8% arthralgia 3.8% NCT01751113 · Phase 4 · registry result, not featured evidence · combination nasophayngitis 6.7% (placebo 5%) chronic obstructive pulmonary disease 4.6% (placebo 9.6%) NCT00523991 · Phase 4 · registry result, not featured evidence chronic obstructive pulmonary disease 6.4% NCT00359788 · Phase 4 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary 15.6% nasopharyngitis 11.5% headache 5.1% NCT02796677 · Phase 3 · registry result, not featured evidence 5 mcg chronic obstructive pulmonary disease 32.9% NCT01126437 · Phase 3 · registry result, not featured evidence 18 mcg chronic obstructive pulmonary disease 33.9% NCT01126437 · Phase 3 · registry result, not featured evidence 2.5 mcg chronic obstructive pulmonary disease 33.8% NCT01126437 · Phase 3 · registry result, not featured evidence 10 μg cough 3.3% (placebo 0%) headache 3.3% (placebo 3%) urinary tract infection 3.3% (placebo 3%) NCT03118765 · Phase 2 · registry result, not featured evidence 40 μg dry mouth 12.9% (placebo 0%) dizziness 3.2% (placebo 6.1%) back pain 0% (placebo 3%) NCT03118765 · Phase 2 · registry result, not featured evidence 20 μg back pain 6.3% (placebo 3%) headache 6.3% (placebo 3%) cough 3.1% (placebo 0%) NCT03118765 · Phase 2 · registry result, not featured evidence 5 mcg nasopharyngitis 9.3% (placebo 4.1%) dyspnoea 2% (placebo 9.5%) NCT01222533 · Phase 2 · registry result, not featured evidence 18 mcg nasopharyngitis 4.8% (placebo 4.1%) dyspnoea 2.1% (placebo 9.5%) NCT01222533 · Phase 2 · registry result, not featured evidence 2.5 mcg dyspnoea 1.4% (placebo 9.5%) nasopharyngitis 1.4% (placebo 4.1%) NCT01222533 · Phase 2 · registry result, not featured evidence 1.25 mcg nasopharyngitis 6.1% (placebo 4.1%) dyspnoea 3.4% (placebo 9.5%) NCT01222533 · Phase 2 · registry result, not featured evidence 5 mcg nasopharyngitis 10.2% chronic obstructive pulmonary disease 5.6% NCT01040403 · Phase 2 · registry result, not featured evidence 10 mcg nasopharyngitis 6.4% chronic obstructive pulmonary disease 5.5% NCT01040403 · Phase 2 · registry result, not featured evidence tiotropium 5 mcg + olodaterol 10 mcg chronic obstructive pulmonary disease 3.6% nasopharyngitis 1.8% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 5 mcg + olodaterol 5 mcg chronic obstructive pulmonary disease 7.3% nasopharyngitis 2.8% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 2.5 mcg + olodaterol 10 mcg nasopharyngitis 3.6% chronic obstructive pulmonary disease 2.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 2.5 mcg + olodaterol 5 mcg nasopharyngitis 7.1% chronic obstructive pulmonary disease 2.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 1.25 mcg + olodaterol 10 mcg nasopharyngitis 7.3% chronic obstructive pulmonary disease 6.4% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 1.25 mcg + olodaterol 5 mcg nasopharyngitis 11% chronic obstructive pulmonary disease 3.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 3 weeks versus 2.142857142857143 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 4 versus Phase 3.
- fTrial phases differ: Phase 2 versus Phase 3.
- gAssessment timepoints differ: 4 weeks versus 52 weeks.
- hAssessment timepoints differ: 120 weeks versus 52 weeks.
- iThe assessment timepoint is not available for both results.
- jPopulation comparability has not been reviewed for 31 of these studies.
- kPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aclidinium bromide
show 3 more results
show 5 more results
show 5 more results
show 5 more results
show 1 more result
+ 18 further endpoints in the CSV export.
Tiotropium bromide
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 104 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide's landscape · Tiotropium bromide's landscape